Great Lakes Advisors LLC Purchases Shares of 184,231 Kenvue Inc. $KVUE

Great Lakes Advisors LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 184,231 shares of the company’s stock, valued at approximately $3,521,000.

Other large investors have also recently made changes to their positions in the company. Physician Wealth Advisors Inc. grew its position in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares during the period. Elyxium Wealth LLC purchased a new stake in shares of Kenvue during the 4th quarter worth about $26,000. MV Capital Management Inc. acquired a new stake in shares of Kenvue during the 4th quarter valued at about $28,000. CoreCap Advisors LLC raised its holdings in Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the period. Finally, Reflection Asset Management purchased a new position in Kenvue during the fourth quarter worth approximately $32,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Barclays upped their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Finally, UBS Group lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.27.

Kenvue Stock Down 1.1%

Shares of KVUE opened at $18.92 on Friday. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $21.78. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $19.04 and a two-hundred day simple moving average of $18.19. The company has a market capitalization of $36.34 billion, a PE ratio of 21.75, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. During the same period in the previous year, the firm posted $0.29 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend is Wednesday, August 12th. This is a boost from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is presently 96.55%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.